A Study to Investigate the Efficacy and Safety of RO5285119 in Participants With Autism Spectrum Disorder (ASD)

  • Autism Spectrum Disorder
Trial Status:

Terminated

This trial runs in
Countries
  • United States
Trial Identifier:

NCT02901431 BP30153

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      For participants enrolled prior to Version 6 of the protocol: This is a Phase II multi-center, randomized, double-blind, 24-week, 3-arm, parallel group, placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics of balovaptan in children and adolescents aged 5-17 years with ASD who are high functioning (intelligence quotient [IQ] greater than or equal to [>=] 70). For participants enrolled according to Version 6 of the protocol: This is a Phase II multi-center, randomized, double-blind, 24-week, parallel group, placebo-controlled, 2-arm study with participants assigned either to a 10 milligram (mg) or equivalent dose of balovaptan, or placebo. All other study parameters remain as stated above. All participants that complete the 24-week treatment period will be eligible to participate in an optional 52-week open-label extension (OLE) during which they will receive balovaptan treatment.

      Hoffmann-La Roche Sponsor
      Phase 2 Phase
      NCT02901431 , BP30153 Trial Identifier
      Placebo, RO5285119 Treatments
      Autism Spectrum Disorder Condition
      Official Title

      A Phase II Multi-Center, Randomized, Double-Blind, 24-Week, Parallel Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Children and Adolescents Age 5-17 With Autism Spectrum Disorder (ASD)

      Eligibility Criteria

      All Gender
      ≥ 5 Years & ≤ 17 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Fluent in English
      • Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for ASD or International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD10) criteria for Autism diagnosis confirmed by Autism Diagnostic Observational Schedule (ADOS-2) criteria
      • Social Responsiveness Scale, second edition (SRS-2) (T-score) >= 66
      • Clinical Global Impressions of Severity (CGI-S) >= 4 (moderately ill) at screening
      • IQ >= 70 as assessed by Wechsler Abbreviated Scale of Intelligence Scale: Second Edition (WASI-II) or Wechsler Preschool and Primary Scale of Intelligence: Fourth Edition (WPPSI-IV) intelligence test
      • Language, hearing, and vision compatible with the study measurements as judged by the investigator

      Inclusion Criteria for the OLE:

      • Have completed the blinded treatment phase of the study OR were required to stop dosing at or before Week 8
      • Have no adverse events that would prohibit starting the OLE
      Exclusion Criteria
      • Initiation of a major change in psychosocial intervention (including investigational) within 4 weeks prior to screening
      • Unstable or uncontrolled clinically significant psychiatric and/or neurological disorder that may interfere with the safety or efficacy endpoints
      • Known personal or family history of cerebral aneurysm
      • Risk of suicidal behavior
      • Seizure within the past 6 months
      • Medical history of alcohol or substance abuse/dependence
      • Concurrent cardio-vascular disease not considered well controlled by the Investigator
      • Clinically significant abnormality on electrocardiogram at screening
      • Concomitant disease or condition (pulmonary, gastro-intestinal, hepatic, renal, metabolic, immunological system, or obesity that could interfere with the conduct of the study
      • Evidence for current gastro-intestinal bleeding, e.g., active stomach ulcer disease
      • History of coagulopathies, bleeding disorders, or blood dyscrasias
      • Positive serology for hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV) 1, or HIV 2
      • Confirmed clinically significant abnormality in parameters of hematology, clinical chemistry, coagulation, or urinalysis
      • Medical history of malignancy if not considered cured
      • Participation in an investigational drug study within 90 days or 5 times the half-life of the investigational molecule (whichever is longer) prior to randomization
      • Loss of blood over 250 milliliters within three months prior to screening
      • Allowed medications have not been stable since 4 weeks before screening, and allowed medications for treatment of epilepsy have not been stable since 3 months before screening
      • Use of prohibited medications within 2 weeks prior to screening visit or 5 times the half-life prior to randomization (whichever is longer)

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on ForPatients in related disease areas.

      Autism Spectrum Disorder

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now